Treatment guide
Oral Medications for Spasticity
Oral medicines may reduce widespread spasms or stiffness, but benefits must be balanced against sedation, dizziness and weakness. Selection and dose adjustment require individualized medical care.
Oral antispasticity medicines act on the brain, spinal cord or muscle to reduce excessive activity. They are often considered when symptoms affect several regions, fluctuate through the day or cannot be managed adequately with rehabilitation and focal treatment alone.
No tablet can selectively weaken only the troublesome part of a movement pattern. Systemic treatment can also reduce useful tone or increase weakness, so the goal and response should be reviewed carefully.
Baclofen
Baclofen acts mainly at GABA-B receptors in the spinal cord. It is widely used for spasticity associated with multiple sclerosis, spinal cord disorders and other neurological conditions. Drowsiness, dizziness, weakness and confusion can occur, particularly as the dose increases or in older adults.
Baclofen should not be stopped suddenly. Abrupt withdrawal can cause rebound spasticity, agitation, hallucinations, seizures, fever and other dangerous symptoms. Dose changes require medical guidance.
Tizanidine
Tizanidine is an alpha-2 adrenergic agonist that reduces excitatory signaling. It may help spasms and tone but can cause sleepiness, dry mouth, dizziness and low blood pressure. Liver monitoring and attention to medication interactions may be needed.
Dantrolene
Dantrolene acts directly on skeletal muscle rather than primarily in the central nervous system. It can reduce contraction but may worsen weakness. Because serious liver injury is possible, prescribing requires careful selection and monitoring.
Benzodiazepines and other agents
Medicines such as diazepam may reduce spasms but can produce sedation, impaired balance, tolerance and dependence. They are generally used selectively. Other agents may be considered for particular conditions, symptoms or nighttime problems, but evidence and approvals vary.
Choosing a medicine
The clinical team considers the neurological diagnosis, whether symptoms are focal or generalized, kidney and liver function, age, fall risk, cognition, breathing, other medicines and daily activities. A drug that reduces nighttime spasms but causes unacceptable daytime sleepiness has not met the overall goal.
Starting with a low dose and increasing gradually may improve tolerability. Some people benefit from timing doses around predictable symptoms, while others require a different strategy. Never alter a prescription based on a website or another person’s experience.
How success should be measured
Useful outcomes include fewer painful spasms, improved sleep, easier transfers, better comfort or reduced caregiver difficulty. A lower tone score without real-life benefit may not justify adverse effects. If function worsens, clinicians should consider whether the person was relying on tone for support.
Combining approaches
Oral medicines are commonly combined with rehabilitation, trigger management, positioning or focal injections. Combining medicines can also increase sedation or other adverse effects. A complete medication list is important, including nonprescription and herbal products.
When to seek urgent help
Contact a clinician promptly for severe sleepiness, falls, fainting, confusion, jaundice, marked weakness or another concerning reaction. Emergency help may be needed for breathing difficulty, severe allergic reaction, seizures or suspected abrupt baclofen withdrawal.
For severe widespread symptoms that do not respond to tolerable oral doses, a specialist may discuss other treatment options, including intrathecal baclofen.
Sources
- Francisco GE, et al. Post-Stroke Spasticity. 2021.
- American Academy of Physical Medicine and Rehabilitation. Spasticity. PM&R KnowledgeNow.
- National Institute for Health and Care Excellence. Treatment with drugs for spasticity.
- Pickard C, et al. Guide to Spasticity Management in Spinal Cord Injury. 2020.
Public-service medical disclaimer: this article provides general education. It does not provide diagnosis or treatment and should not guide an individual medical decision.
How clinicians choose and monitor an oral medicine
The decision is shaped by the distribution of symptoms, the underlying neurological condition, other medicines, kidney and liver health, seizure risk, blood pressure, daytime responsibilities and the person’s treatment goals. Oral medicines circulate throughout the body, so they may be more relevant when spasticity is generalized than when only a small number of muscles are causing a focal problem. For focal post-stroke spasticity, current stroke recommendations generally favor a targeted treatment such as botulinum toxin when appropriate.
Start low, change carefully
Many antispastic medicines are introduced at a low dose and adjusted gradually. This gives the care team a chance to balance benefit against sleepiness, dizziness, weakness, low blood pressure, confusion or reduced concentration. The right dose is not simply the highest dose tolerated. It is the dose that supports the agreed goal without creating a more important problem, such as unsafe walking, impaired transfers or difficulty staying alert at work.
What to track after starting or changing treatment
- The specific symptom or activity the medicine is intended to improve.
- Timing of benefit in relation to each dose.
- Daytime sleepiness, dizziness, falls, confusion or new weakness.
- Changes in walking, transfers, hand use, personal care and sleep.
- Any missed doses, new prescriptions or over-the-counter products.
Do not stop abruptly without advice
Some medicines, particularly baclofen, can cause serious withdrawal symptoms if stopped suddenly after regular use. A prescriber should provide a tapering plan when treatment is discontinued. If a dose is missed, do not double the next dose unless a clinician or pharmacist specifically instructs you to do so. Seek urgent medical advice for severe confusion, hallucinations, seizures, very high fever, marked rebound stiffness or breathing difficulty.
Medication review should remain connected to rehabilitation. A medicine may create an opportunity for more comfortable movement or care, but therapy, positioning, equipment and task practice often determine whether that physiological change becomes a useful daily-life improvement.
Questions for the prescriber or pharmacist
- What exact goal should this medicine improve, and when should a benefit be noticeable?
- Which adverse effects require a call, and which require urgent care?
- Does the dose need adjustment for kidney or liver function?
- Could it interact with alcohol, sleep medicines, pain medicines or other sedating drugs?
- What is the safe plan if treatment needs to be stopped?
Keep the answer with the medication list and share it with every clinician involved in care.
Bring the medication list to every review, including non-prescription products and supplements. Consistent documentation helps the team recognize interactions, duplicated treatment and changes that may explain new fatigue, weakness or falls.